June 23 (Reuters) - Forte Biosciences Inc FBRX.O:
FORTE BIOSCIENCES ANNOUNCES POSITIVE DATA IN FB102 CELIAC DISEASE PHASE 1B STUDY
FORTE BIOSCIENCES INC - FB102 SHOWS SIGNIFICANT BENEFIT ON VCIEL ENDPOINT
FORTE BIOSCIENCES INC - FB102 SHOWS DECLINE IN CD3-POSITIVE T CELLS DENSITY
Source text: ID:nBwbSLHFSa
Further company coverage: FBRX.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.